AI powered NemaLife combines AI-assisted microfluidics with in vivo C. elegans testing to accelerate high throughput biology, offering a faster alternative to mouse models. This positions them to engage biotech, nutraceutical, and pharma firms seeking faster preclinical readouts and cost-efficient R&D partnerships.

CRUELTY FREE The 3R-compliant, cruelty-free platform appeals to companies aiming for ethical, scalable in vivo data. Target customers include brands prioritizing humane research methods and those facing regulatory scrutiny or consumer demand for animal-free testing solutions.

Preclinical Expertise With strong preclinical expertise in gut, brain, muscle, metabolic health, cognitive health, and aging, NemaLife can offer co-created readouts and custom tech platforms aligned with key health claims. This enables cross-sell opportunities into dietary supplements, probiotics, and functional foods.

Strategic Partnerships Recent collaborations with Motif Ingredients and NIH funding indicate a track record of industry and government engagement. Leverage these relationships to pursue partnerships with large food tech, nutraceuticals, and pharma players seeking in vivo validation and product potency assessment.

Growth Signals Revenue range and grant activity suggest scaling potential with room to expand services, expand AI tool offerings, and attract larger clients. Focus on expanding enterprise type engagements, multi-project programs, and ongoing R&D partnerships for long-term value.